Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer

Greeshma Rajeev-Kumar; Rohan R Katipally; Shen Li; Benjamin D Shogan; Kinga S Olortegui; Janet Chin; Blase N Polite; Stanley L Liauw

doi:10.1097/PPO.0000000000000732

Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer

Cancer J. 2024 Jul-Aug;30(4):256-263. doi: 10.1097/PPO.0000000000000732.

Authors

Greeshma Rajeev-Kumar¹, Rohan R Katipally¹, Shen Li², Benjamin D Shogan³, Kinga S Olortegui³, Janet Chin⁴, Blase N Polite⁴, Stanley L Liauw¹

Affiliations

¹ From the Department of Radiation and Cellular Oncology.
² Sections of Surgical Oncology.
³ Colon and Rectal Surgery, Department of Surgery.
⁴ Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL.

PMID: 39042777
DOI: 10.1097/PPO.0000000000000732

Abstract

Locally advanced rectal cancer has historically been treated with multimodal therapy consisting of radiation therapy, chemotherapy, and total mesorectal excision. However, recent prospective trials and registry studies have demonstrated similar disease outcomes with nonoperative management for patients who experience an excellent clinical response to radiation and chemotherapy. This article reviews data regarding nonoperative management for rectal cancer, and highlights current challenges and limitations in a point-counterpoint format, in the context of two clinical cases.

Publication types

Review
Case Reports

MeSH terms

Combined Modality Therapy / methods
Disease Management
Female
Humans
Male
Middle Aged
Rectal Neoplasms* / diagnosis
Rectal Neoplasms* / pathology
Rectal Neoplasms* / therapy
Treatment Outcome